噬菌体在实体器官移植中的应用

吴楠楠; 朱同玉

doi:10.3969/j.issn.1674-7445.2019.04.010

噬菌体在实体器官移植中的应用

doi: 10.3969/j.issn.1674-7445.2019.04.010

吴楠楠,
朱同玉^,

201508 上海市公共卫生临床中心上海噬菌体与耐药研究所复旦大学附属中山医院上海市器官移植重点实验室

基金项目:

国家自然科学基金面上项目 81873621

上海市卫计委卫生行业临床研究专项青年项目 20184Y0274

详细信息

作者简介:
吴楠楠，男，1986年生，博士，助理研究员，研究方向为病毒学，Email：wunannan@shphc.org.cn

朱同玉，主任医师、教授、博士研究生导师，现任上海市公共卫生临床中心院长，复旦大学附属中山医院副院长，上海市器官移植重点实验室主任，上海噬菌体与耐药研究所所长。兼任上海医学会器官移植分会主任委员，中国医师协会器官移植分会常委，美国密西西比大学客座教授。担任《Am J Transplant（中文版）》杂志副主编，《器官移植》杂志常务编委，《Int J Clin Pract》、《中华器官移植杂志》、《国际移植与血液净化杂志》等杂志编委，担任《New Engl J Med》、《Am J Transplant》、《Transplantation》、《J Clin Bioinforma》等杂志审稿专家。长期从事肾移植临床及研究工作，近年来对移植术后的感染防控尤为关注，2018年起主持国内首个噬菌体治疗超级耐药细菌感染临床试验。在《Cell Death Dis》、《Emerg Microbes Infect》、《Transplantation》、《Nat Immunol》、《Blood》、《Leukemia Res》等杂志发表学术论文200余篇。荣获上海市医学领军人才、上海市优秀学科带头人、上海市领军人才等荣誉

通讯作者:
朱同玉，男，1966年生，博士，教授，主任医师，研究方向为肾移植与泌尿外科，Email：tyzhu@fudan.edu.cn

中图分类号: R617, Q939.48
计量
- 文章访问数: 193
- HTML全文浏览量: 239
- PDF下载量: 19
- 被引次数: 0
出版历程
- 收稿日期: 2019-04-25
- 网络出版日期: 2021-01-19
- 刊出日期: 2019-07-15

摘要

摘要: 耐药细菌感染是当前人类面临的共同威胁。对于器官移植受者来说，围手术期面临着细菌院内感染的威胁，术后免疫抑制也给耐药细菌感染提供了可乘之机。但新型抗生素筛选速度远远滞后于细菌的变异速度，传统抗生素疗法已无法满足临床应对超级耐药细菌的需求，拥有百年历史的噬菌体疗法重新回到人们的视野。噬菌体可用于预防、诊断和治疗超级细菌感染，在器官移植领域有很大的应用空间。
- 实体器官移植 /
- 噬菌体 /
- 细菌性感染 /
- 围手术期 /
- 抗生素 /
- 院内感染 /
- 耐药

HTML全文

参考文献(45)

[1]	THACKER PD. Set a microbe to kill a microbe: drug resistance renews interest in phage therapy[J]. JAMA, 2003, 290(24):3183-3185. DOI: 10.1001/jama.290.24.3183.
[2]	SUMMERS WC. Bacteriophage therapy[J]. Annu Rev Microbiol, 2001, 55:437-451. doi: 10.1146/annurev.micro.55.1.437
[3]	安瑞.噬菌体治疗的前世、今生与未来——对话微生物学界噬菌体专家[J].科学通报, 2017, 62(23):2577-2580. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=kxtb201723001 AN R. Phage-based and future:dialogue bacteriophage expert in microbiology[J].Chin Sci Bulletin, 2017, 62(23):2577-2580. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=kxtb201723001
[4]	BOUCHER HW, TALBOT GH, BRADLEY JS, et al. Bad bugs, no drugs: no ESKAPE! an update from the Infectious Diseases Society of America[J]. Clin Infect Dis, 2009, 48(1):1-12. DOI: 10.1086/595011.
[5]	SUAY-GARCÍA B, PÉREZ-GRACIA MT. Future prospects for neisseria gonorrhoeae treatment[J]. Antibiotics (Basel), 2018, 7(2): E49. DOI: 10.3390/antibiotics7020049.
[6]	RHOADS DD, WOLCOTT RD, KUSKOWSKI MA, et al. Bacteriophage therapy of venous leg ulcers in humans: results of a phase Ⅰ safety trial[J]. J Wound Care, 2009, 18(6):237-238, 240-243. doi: 10.12968/jowc.2009.18.6.42801
[7]	WRIGHT A, HAWKINS CH, ANGGÅRD EE, et al.A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistant pseudomonas aeruginosa; a preliminary report of efficacy[J]. Clin Otolaryngol, 2009, 34(4):349-357. DOI: 10.1111/j.1749-4486.2009.01973.x.
[8]	JAULT P, LECLERC T, JENNES S, et al. Efficacy and tolerability of a cocktail of bacteriophages to treat burn wounds infected by pseudomonas aeruginosa (PhagoBurn): a randomised, controlled, double-blind phase 1/2 trial[J]. Lancet Infect Dis, 2019, 19(1):35-45. DOI: 10.1016/S1473-3099(18)30482-1.
[9]	SARKER SA, MCCALLIN S, BARRETTO C, et al. Oral T4-like phage cocktail application to healthy adult volunteers from Bangladesh[J]. Virology, 2012, 434(2):222-232. DOI: 10.1016/j.virol.2012.09.002.
[10]	SARKER SA, SULTANA S, REUTELER G, et al. Oral phage therapy of acute bacterial diarrhea with two coliphage preparations: a randomized trial in children from Bangladesh[J]. EBioMedicine, 2016, 4:124-137. DOI: 10.1016/j.ebiom.2015.12.023.
[11]	SARKER SA, BERGER B, DENG Y, et al. Oral application of escherichia coli bacteriophage: safety tests in healthy and diarrheal children from Bangladesh[J]. Environ Microbiol, 2017, 19(1):237-250. DOI: 10.1111/1462-2920.13574.
[12]	首例超级细菌感染患者经噬菌体治疗痊愈[EB/OL].(2018-08-15).http://www.sh.chinanews.com/yljk/2018-08-15/43418.shtml.
[13]	LEE KC, JOORY K, MOIEMEN NS. History of burns: the past, present and the future[J]. Burns Trauma, 2014, 2(4):169-180. DOI: 10.4103/2321-3868.143620.
[14]	BARTOLETTI M, GIANNELLA M, TEDESCHI S, et al. Multidrug-resistant bacterial infections in solid organ transplant candidates and recipients[J]. Infect Dis Clin North Am, 2018, 32(3):551-580. DOI: 10.1016/j.idc.2018.04.004.
[15]	FLORESCU DF, MCCARTNEY AM, QIU F, et al. Staphylococcus aureus infections after liver transplantation[J]. Infection, 2012, 40(3):263-269. DOI: 10.1007/s15010-011-0224-3.
[16]	SHIELDS RK, CLANCY CJ, MINCES LR, et al. Staphylococcus aureus infections in the early period after lung transplantation: epidemiology, risk factors, and outcomes[J]. J Heart Lung Transplant, 2012, 31(11):1199-1206. DOI: 10.1016/j.healun.2012.08.012.
[17]	GIANNELLA M, BARTOLETTI M, MORELLI MC, et al. Risk factors for infection with carbapenem-resistant Klebsiella pneumoniae after liver transplantation: the importance of pre- and posttransplant colonization[J]. Am J Transplant, 2015, 15(6):1708-1715. DOI: 10.1111/ajt.13136.
[18]	FREIRE MP, OSHIRO IC, PIERROTTI LC, et al. Carbapenem-resistant enterobacteriaceae acquired before liver transplantation: impact on recipient outcomes[J]. Transplantation, 2017, 101(4):811-820.DOI: 10.1097/TP.0000000000001620.
[19]	MCDERMOTT H, SKALLY M, O'ROURKE J, et al. Vancomycin-resistant enterococci (VRE) in the intensive care unit in a nonoutbreak setting: identification of potential reservoirs and epidemiological associations between patient and environmental VRE[J]. Infect Control Hosp Epidemiol, 2018, 39(1):40-45. DOI: 10.1017/ice.2017.248.
[20]	KAMPMEIER S, KOSSOW A, CLAUSEN LM, et al. Hospital acquired vancomycin resistant enterococci in surgical intensive care patients-a prospective longitudinal study[J]. Antimicrob Resist Infect Control, 2018, 7:103. DOI: 10.1186/s13756-018-0394-1.
[21]	BANACH DB, PEAPER DR, FORTUNE BE, et al. The clinical and molecular epidemiology of pre-transplant vancomycin-resistant enterococci colonization among liver transplant recipients[J]. Clin Transplant, 2016, 30(3):306-311. DOI: 10.1111/ctr.12690.
[22]	TIMSIT JF, BASSETTI M, CREMER O, et al. Rationalizing antimicrobial therapy in the ICU:a narrative review[J]. Intensive Care Med, 2019, 45(2):172-189. DOI: 10.1007/s00134-019-05520-5.
[23]	BODRO M, SABÉ N, TUBAU F, et al. Extensively drug-resistant pseudomonas aeruginosa bacteremia in solid organ transplant recipients[J]. Transplantation, 2015, 99(3):616-622. DOI: 10.1097/TP.0000000000000366.
[24]	LIU T, ZHANG Y, WAN Q. Pseudomonas aeruginosa bacteremia among liver transplant recipients[J]. Infect Drug Resist, 2018, 11:2345-2356. DOI: 10.2147/IDR.S180283.
[25]	AGUIAR EB, MACIEL LC, HALPERN M, et al. Outcome of bacteremia caused by extended-spectrum β-lactamase-producing enterobacteriaceae after solid organ transplantation[J]. Transplant Proc, 2014, 46(6):1753-1756. DOI: 10.1016/j.transproceed.2014.05.003.
[26]	ESPINAR MJ, MIRANDA IM, COSTA-DE-OLIVEIRA S, et al. Urinary tract infections in kidney transplant patients due to escherichia coli and Klebsiella pneumoniae-producing extended-spectrum β-lactamases: risk factors and molecular epidemiology[J].PLoS One, 2015, 10(8):e0134737. DOI: 10.1371/journal.pone.0134737.
[27]	BAKTASH A, TERVEER EM, ZWITTINK RD, et al. Mechanistic insights in the success of fecal microbiota transplants for the treatment of clostridium difficile infections[J]. Front Microbiol, 2018, 9:1242. DOI: 10.3389/fmicb.2018.01242.
[28]	BOODMAN E. To save a young woman besieged by superbugs, scientists hunt a killer virus [EB/OL]. (2017-11-10). https://www.statnews.com/2017/11/10/superbug-phage-mallory-smith.
[29]	BOODMAN E. A patient's legacy: researchers work to make phage therapy less of a long shot [EB/OL]. (2017-11-28).https://www.statnews.com/2017/11/28/phage-therapy-mallory-smith.
[30]	ASLAM S YG, DAN J, REED S, et al. 373 - bacteriophage treatment in a lung transplant recipient in: 38th Annual International Society for Heart & Lung Transplantation (ISHLT) Meeting & Scientific Sessions, April 13, 2018[C]. France : Nice, 2018.
[31]	HO YH, TSENG CC, WANG LS, et al. Application of bacteriophage-containing aerosol against nosocomial transmission of carbapenem-resistant acinetobacter baumannii in an intensive care unit[J]. PLoS One, 2016, 11(12):e0168380. DOI: 10.1371/journal.pone.0168380.
[32]	GÓRSKI A, DĄBROWSKA K, MIĘDZYBRODZKI R, et al. Phages and immunomodulation[J]. Future Microbiol, 2017, 12:905-914. DOI: 10.2217/fmb-2017-0049.
[33]	ALIBERTI S, REYES LF, FAVERIO P, et al. Global initiative for meticillin-resistant staphylococcus aureus pneumonia (GLIMP): an international, observational cohort study[J]. Lancet Infect Dis, 2016, 16(12):1364-1376. DOI: 10.1016/S1473-3099(16)30267-5.
[34]	LO DK, MUHLEBACH MS, SMYTH AR. Interventions for the eradication of meticillin-resistant staphylococcus aureus (MRSA) in people with cystic fibrosis[J]. Cochrane Database Syst Rev, 2018, 7:CD009650.DOI: 10.1002/14651858.CD009650.pub4.
[35]	RODRÍGUEZ-SEVILLA G, GARCÍA-COCA M, ROMERA-GARCÍA D, et al. Non-tuberculous mycobacteriamultispecies biofilms in cystic fibrosis: development of an in vitro mycobacterium abscessus and pseudomonas aeruginosa dual species biofilm model[J]. Int J Med Microbiol, 2018, 308(3):413-423.DOI: 10.1016/j.ijmm.2018.03.003.
[36]	GRANCHELLI AM, ADLER FR, KEOGH RH, et al. Microbial interactions in the cystic fibrosis airway[J]. J Clin Microbiol, 2018, 56(8):e00354-e00318. DOI: 10.1128/JCM.00354-18.
[37]	ARROYO V, MOREAU R, KAMATH PS, et al. Acute-on-chronic liver failure in cirrhosis[J]. Nat Rev Dis Primers, 2016, 2:16041. DOI: 10.1038/nrdp.2016.41.
[38]	EKSER B, MANGUS RS. Spontaneous bacterial peritonitis[J]. Lancet, 2017, 389(10070):735. DOI: 10.1016/S0140-6736(16)30782-6.
[39]	BLAIR BM. Safe living following solid organ transplantation[J]. Surg Clin North Am, 2019, 99(1):153-161. DOI: 10.1016/j.suc.2018.09.011.
[40]	PENG H, CHEN IA. Rapid colorimetric detection of bacterial species through the capture of gold nanoparticles by chimeric phages[J]. ACS Nano, 2019, 13(2):1244-1252. DOI: 10.1021/acsnano.8b06395.
[41]	YUE H, HE Y, FAN E, et al. Label-free electrochemiluminescent biosensor for rapid and sensitive detection of pseudomonas aeruginosa using phage as highly specific recognition agent[J]. Biosens Bioelectron, 2017, 94:429-432.DOI: 10.1016/j.bios.2017.03.033.
[42]	HE Y, SHI Y, LIU M, et al. Nonlytic recombinant phage tail fiber protein for specific recognition of pseudomonas aeruginosa[J]. Anal Chem, 2018, 90(24):14462-14468. DOI: 10.1021/acs.analchem.8b04160.
[43]	FAROOQ U, YANG Q, ULLAH MW, et al. Bacterial biosensing: recent advances in phage-based bioassays and biosensors[J]. Biosens Bioelectron, 2018, 118:204-216. DOI: 10.1016/j.bios.2018.07.058.
[44]	BROGAN DM, MOSSIALOS E. A critical analysis of the review on antimicrobial resistance report and the infectious disease financing facility[J]. Global Health, 2016, 12:8. DOI: 10.1186/s12992-016-0147-y.
[45]	KILCHER S, LOESSNER MJ. Engineering bacteriophages as versatile biologics[J]. Trends Microbiol, 2019, 27(4):355-367. DOI: 10.1016/j.tim.2018.09.006.